Here are three reasons why there are better opportunities than INCY and a stock we'd rather own. Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment ...

Even though the stock has become cheaper, we don't have much confidence in Incyte. Here are three reasons why there are better opportunities than INCY and a stock we'd rather own. Founded in 1991 and ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The company’s shares closed yesterday at $62.01.

Incyte (INCY – Research Report) received a Hold rating and price target from William Blair analyst Matt Phipps today. The company’s shares closed yesterday at $61.92. Easily identify stocks ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis ...

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (BMV:INCY) from Outperform to Market Perform. There are 1,211 funds or institutions reporting positions in ...

Shares of INCY stock opened at $60.00 on Tuesday. The company’s fifty day simple moving average is $71.29 and its two-hundred day simple moving average is $70.27. The company has a debt-to ...

In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024 ...

VIENNA, Austria—Patients with chronic heart failure who require cardiac resynchronization therapy (CRT) fare better when left bundle branch (LBB) pacing is used over traditional biventricular (BiV) ...

In the preceding three months, 6 analysts have released ratings for Incyte INCY, presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ...